Podcasts about Health Canada

When avid outdoor adventurers Jaime Hackett and Erin Prohaska couldn't find a bug spray that actually worked and felt good on their skin, they decided to create their own. That's how Bite was born — a Toronto-based brand on a mission to make bug protection clean, non-toxic, and enjoyable to use.In this episode, the co-founders share the full story behind Bite's creation, from the personal frustrations that sparked their idea to the uphill climb of bringing a new kind of wellness product to market. We talk about what it takes to build a purpose-led brand in a highly regulated category, the red tape of Health Canada approvals, navigating a tough retail environment, and the steep learning curve of entrepreneurship in a product-based business. Jaime and Erin open up about the unexpected roadblocks, the grind of building something from the ground up, and the relentless belief that a better solution was possible.This is a conversation about the ups and downs of brand-building, and changing the way we think about the products we use every day — even bug spray.This season of our podcast is brought to you by TD Canada Women in Enterprise. TD is proud to support women entrepreneurs and help them achieve success and growth through its program of educational workshops, financing and mentorship opportunities! Please find out how you can benefit from their support! Visit: TBIF: thebrandisfemale.com // TD Women in Enterprise: td.com/ca/en/business-banking/small-business/women-in-business // Follow us on Instagram: instagram.com/thebrandisfemale

We talk about the excise tax and the changes needed, Ghost Drops is fighting Health Canada, a new lobbying group for cannabis, two people on every shift in Victoria cannabis stores and we stop on Cultivar Corner, brought to you by Up In Smoke, we sample from Rocky Mountain Cannabis their delicious sativa, Red Congolese.Cannabis lobbying groupNo solo staffing in VictoriaExcise needs to be fixedRocky Mountain Cannabis Red CongoleseGhost drops fights Health CanadaSome public fighting

What's in your drinking water? On Prince Edward Island, the provincial testing program shows potable water in some communities have higher levels of toxic “forever chemicals” than is recommended by Health Canada. To what extent this affects other provinces is unclear – PEI is currently the only province that systematically tests water supplies to make sure they hit federal targets for toxic chemicals.Patrick White is The Globe's water reporter. He explains the safety concerns surrounding “forever chemicals” in our water, why the health agency revamped its guidelines and looks into why other provinces are slow to adapt.Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com

This episode of The Food Professor Podcast is steeped in insights, storytelling, and smoky Texas flavour. Hosts Michael LeBlanc and Dr. Sylvain Charlebois kick off with a deep dive into the state of Canadian agri-food policy, tariffs, and food inflation before welcoming a very special guest: Tonia Jahshan, Founder and CEO of Sipology.Broadcasting remotely from Texas, Sylvain shares updates from his new role as head of the prestigious Masters in Agribusiness program at Texas A&M University—ranked #1 in the U.S. and #3 globally. He offers behind-the-scenes insights into the world of American ag education, donor-funded infrastructure, and his leadership plans. Amidst meetings with deans and exploring campus, Sylvain visits a Texas institution of another kind—Buc-ee's, the legendary convenience store-meets-theme-park known for its brisket, wall of jerky, and award-winning bathrooms. The hosts revel in Buc-ee's cult status and then Michael highlights the newly released Texas Monthly Top 50 BBQ list, the Michelin Guide of Texas barbecue. Sylvain, a BBQ enthusiast, is already planning future brisket pilgrimages.  Congrats to our guest on the #pod from earlier this year Chuck Charnichart from Barb's BQ for making the list!!From Texas to Toronto, the episode pivots to policy with an analysis of Prime Minister Mark Carney's new mandate letter. Sylvain critiques its lack of clarity for the agri-food sector, calling for a shift from farm-gate thinking to value-chain strategy. The hosts then turn to the thorny issue of tea tariffs, which are hitting Canadian importers hard despite recent government reprieves. With tea being a $1.3 billion market in Canada—and nearly all of it imported—these tariffs are creating real cost pressures. The duo also revisits the long-running bread price-fixing investigation, discussing Loblaw's recent $500 million class action settlement and why the Competition Bureau's probe remains unresolved.In the second half of the episode, Tonia Jahshan joins the pod live from the SIAL Canada show floor. The inspirational founder of Sipology (formerly Steeped Tea) shares her origin story: how a single sip of loose-leaf Earl Grey in Nova Scotia after a miscarriage led to a wellness-focused tea empire. From launching a side hustle to pitching on Dragons' Den, growing to 8,000 consultants, and creating Health Canada-approved products like menopause relief teas and fizzy matchas, Tonia's entrepreneurial journey is one of resilience, reinvention, and remarkable growth. Now expanding globally and embracing an omni-channel model, she's brewing up a bold new future for Sipology.With a rich mix of policy insights, business strategy, entrepreneurial inspiration—and a side of Texas BBQ—this episode is a flavourful must-listen. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

Digital Health Canada turns 50 this year! This season on the podcast, we are exploring how far we've come and re-imagining where we can go next – as an association and a sector. To kick off the party, we welcome two Digital Health Canada presidents, from the association's early and current days.  Guests: Denis Protti, Professor Emeritus, Health Information Science, University of Victoria Chris Carvalho, CEO, Carveira Group Consulting Inc. Learn More: Health Information Science at the University of Victoria Digital Health Canada's 50th Anniversary celebrations Episode Summary: 00:00 Introduction and Welcome 00:22 Celebrating 50 Years of Digital Health Canada 00:47 Meet the Presidents: Denis Protti and Chris Carvalho 07:44 Founding the Health Information Science Program 15:47 The Early Days of Digital Health Canada (COACH) 22:59 The Evolution of Digital Health Canada 28:03 Reflections on Leadership and Progress 36:29 Digital Health Canada's 50th Anniversary Celebrations 38:14 Closing Remarks and Call to Action Music: RetroFuture Clean and Breakdown, by Kevin MacLeod. Used under Creative Commons.

MONOLOGUE Health Canada's Deadly Deception: Complicity in mRNA Vaccine Carnage NEWSMAKER Trump: Golden Dome will cost around $175B, be ‘fully operational' in three years https://defensescoop.com/2025/05/20/trump-golden-dome-cost-175-billion-fully-operational-three-years/   Douglas Ernest U.S. Army war veteran and entrepreneur. Author of The Spirit of a True Patriot: The Inspiring Story of Ret. Captain Douglas J. Ernest OPEN LINES THE SOFA CINEFILE Nick Soter reviews Back to the Future, the 1985 sci-fi family favourite starring Michael J. Fox and Christopher Lloyd THE LIMRIDDLER Folks at the TableFixture to fit all the folks at the table.Organ of nature to sunlight enable.Flip through a bookWith a cursory look.Emblem of ice hockey's frustrating fable. NEWSMAKER Israeli embassy staffers killed in Washington DC, suspect yelled ‘Free Palestine' https://www.westernstandard.news/international/israeli-embassy-staffers-killed-in-washington-dc-suspect-yelled-free-palestine/64932 Christopher Oldcorn is the Managing Editor of the Saskatchewan Standard. OPEN LINES NEWMAKER Canada can save the planet by feverishly pumping natural gas, report says https://nationalpost.com/opinion/first-reading-report-canada-save-planet-producing-lng  Dan McTeague, former longtime Liberal MP and President of Canadians for Affordable Energy affordable energy dot C-A. LIMRIDDLE ANSWER AND WINNERS The Answer to this week's Limriddle is: Leaf The first 5 to answer correctly were: 1. Christine De Civita, Stoney Creek, Ontario 2. Michael Dibblee, Vancouver, British Columbia 3. Amy Lou Hoo, East York, Ontario 4. Thomas LeBaron, Haliburton, Ontario 5. Joan- Marie Dibblee Markham, Ontario Fixture to fit all the folks at the table. A leaf is an extra section inserted into a dining table to increase seating capacity. There is no specific reference in the Bible to a leaf in the table at the Last Supper but Leonardo likely needed one so he could fit everybody in the painting. Organ of nature to sunlight enable. The leaf is considered an organ of a plant, performing the essential function of photosynthesis. Flip through a book With a cursory look. To leaf through a book is to casually flip the pages without paying much attention to content. Emblem of ice hockey's frustrating fable. The maple leaf is the emblem of the Toronto Maple Leafs, who last won the Stanley Cup in 1967. Technically, a fable is a short, fictional story with a moral. Sadly, the Leafs' story is none of these. Learn more about your ad choices. Visit megaphone.fm/adchoices

JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, “Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation.” Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multigene panels compared with single-gene BRAF testing to guide therapeutic decisions in advanced melanoma. Transcript Dr. Rafeh Naqash:Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Podcast Editor for JCO Precision Oncology and Assistant Professor at the OU Health Stephenson Cancer Center in the University of Oklahoma. Today, we are excited to be joined by Dr. Dean A. Regier, Director at the Academy of Translational Medicine, Associate Professor at the School of Population and Public Health, UBC Senior Scientist at the British Columbia Cancer Research Institute, and also the senior author of the JCO Precision Oncology article entitled "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." At the time of this recording, our guest's disclosures will be linked in the transcript. Dean, welcome to our podcast and thank you for joining us today. Dr. Dean Regier:Thank you. I'm delighted to be here. Dr. Rafeh Naqash:So, obviously, you are from Canada, and medicine, or approvals of drugs to some extent, and in fact approvals of gene testing to some extent is slightly different, which we'll come to learn about more today, compared to what we do in the US—and in fact, similarly, Europe versus North America to a large extent as well. Most of the time, we end up talking about gene testing in lung cancer. There is a lot of data, a lot of papers around single-gene panel testing in non-small cell lung cancer versus multigene testing. In fact, a couple of those papers have been published in JCO PO, and it has shown significant cost-effectiveness and benefit and outcomes benefit in terms of multigene testing. So this is slightly, you know, on a similar approach, but in a different tumor type. So, could you tell us first why you wanted to investigate this question? What was the background to investigating this question? And given your expertise in health economics and policy, what are some of the aspects that one tends or should tend to understand in terms of cost-effectiveness before we go into the results for this very interesting manuscript? Dr. Dean Regier:Yeah, of course, delighted to. So, one of the reasons why we're deeply interested in looking at comparative outcomes with respect to single- versus multigene testing— whether that's in a public payer system like Canada or an insurer system, a private system in the United States— is that the question around does multigene versus single-gene testing work, has not typically tested in randomized controlled trials. You don't have people randomized to multigene versus single-gene testing. And what that does, it makes the resulting evidence base, whether it's efficacy, safety, or comparative cost-effectiveness, highly uncertain. So, the consequence of that has been uneven uptake around the world of next-generation sequencing panels. And so if we believe that next-gen sequencing panels are indeed effective for our patients, we really need to generate that comparative evidence around effectiveness and cost-effectiveness. So we can go to payers, whether it be single payer or a private insurer, to say, "Here are the comparative outcomes." And when I say that uptake has been uneven, uptake there's been actually plenty, as you know, publications around that uneven uptake, whether it be in Europe, in the United States, in Canada. And so we're really interested in trying to produce that evidence to create the type of deliberations that are needed to have these types of technologies accessible to patients. And part of those deliberations, of course, is the clinical, but also in some contexts, cost-effectiveness. And so, we really start from the perspective of, can we use our healthcare system data, our learning healthcare system, to generate that evidence in a way that emulates a randomized controlled trial? We won't be able to do these randomized controlled trials for various, like really important and and reasons that make sense, quite frankly. So how can we mimic or emulate randomized controlled trials in a way that allows us to make inference around those outcomes? And for my research lab, we usually think through how do we do causal inference to address some of those biases that are inherent in observational data. So in terms of advanced melanoma, we were really interested in this question because first of all, there have been no randomized controlled trials around next-gen sequencing versus single-gene testing. And secondly, these products, these ICIs, immune checkpoint inhibitors, and BRAF and MEK inhibitors, they are quite expensive. And so the question really becomes: are they effective? And if so, to what extent are they cost-effective? Do they provide a good reason to have information around value for money? Dr. Rafeh Naqash:So now going to the biology of melanoma, so we know that BRAF is one of the tumor-agnostic therapies, it has approvals for melanoma as well as several other tumor types. And in fact, I do trials with different RAF-RAS kinase inhibitors. Now, one of the things that I do know is, and I'm sure some of the listeners know, is the DREAMseq trial, which was a melanoma study that was an NCI Cooperative Group trial that was led by Dr. Mike Atkins from Georgetown a couple of years back, that did show survival benefit of first-line immunotherapy sequencing. It was a sequencing study of whether to do first-line BRAF in BRAF-mutant melanoma followed by checkpoint inhibitors, or vice versa. And the immune checkpoint inhibitors followed by BRAF was actually the one that showed benefit, and the trial had to stop early, was stopped early because of the significant benefit seen. So in that context, before we approach the question of single-gene versus multigene testing in melanoma, one would imagine that it's already established that upfront nivolumab plus ipilimumab, for that matter, doublet checkpoint inhibitor therapy is better for BRAF-mutant melanoma. And then there's no significant other approvals for melanoma for NRAS or KIT, you know, mucosal melanomas tend to have KIT mutations, for example, or uveal melanomas, for that matter, have GNAQ, and there's no targeted therapies. So, what is the actual need of doing a broader testing versus just testing for BRAF? So just trying to understand when you started looking into this question, I'm sure you kind of thought about some of these concepts before you delved into that. Dr. Dean Regier:I think that is an excellent question, and it is a question that we asked ourselves: did we really expect any differences in outcomes between the testing strategies? And what did the real-world implementation, physician-guided, physician-led implementation look like? And so, that was kind of one of the other reasons that we really were interested is, why would we go to expanded multigene panel sequencing at all? We didn't really expect or I didn't expect an overall survival a priori. But what we saw in our healthcare system, what happened in our healthcare system was the implementation in 2016 of this multigene panel. And this panel covered advanced melanoma, and this panel cost quite a bit more than what they were doing in terms of the single-gene BRAF testing. And so when you're a healthcare system, you have to ask yourself those questions of what is the additional value associated with that? And indeed, I think in a healthcare system, we have to be really aware that we do not actually follow to the ideal extent randomized controlled trials or trial settings. And so that's the other thing that we have to keep in mind is when these, whether it's an ICI or a BRAF MEK inhibitor, when these are implemented, they do not look like randomized controlled trials. And so, we really wanted to emulate not just a randomized controlled trial, but a pragmatic randomized controlled trial to really answer those real-world questions around implementation that are so important to decision making. Dr. Rafeh Naqash:Sure. And just to understand this a little better: for us in the United States, when we talk about multigene testing, we generally refer to, these days, whole-exome sequencing with whole-transcriptome sequencing, which is like the nuclear option of of the testings, which is not necessarily cheap. So, when you talk about multigene testing in your healthcare system, what does that look like? Is it a 16-gene panel? Is it a 52-gene panel? What is the actual makeup of that platform? Dr. Dean Regier:Excellent question. Yeah, so at the time that this study is looking at, it was 2016, when we, as BC Cancer—so British Columbia is a population right now of 5.7 million people, and we have data on all those individuals. We are one healthcare system providing health care to 5.7 million people. In 2016, we had what I call our "home-brew" multigene panel, which was a 53-gene panel that was reimbursed as standard of care across advanced cancers, one of them being advanced melanoma. We have evolved since then. I believe in 2022, we are using one of the Illumina panels, the Focus panel. And so things have changed; it's an evolving landscape. But we're specifically focused on the 53-gene panel. It was called OncoPanel. And that was produced in British Columbia through the Genome Sciences Centre, and it was validated in a single-arm trial mostly around validity, etc. Dr. Rafeh Naqash:Thank you for explaining that. So now, onto the actual meat and the science of this project. So, what are some of the metrics from a health economy standpoint that you did look at? And then, methodology-wise, I understand, in the United States, we have a fragmented healthcare system. I have data only from my institution, for that matter. So we have to reach out to outside collaborators and email them to get the data. And that is different for you where you have access to all the data under one umbrella. So could you speak to that a little bit and how that's an advantage for this kind of research especially? Dr. Dean Regier:Yeah. In health economics, we look at the comparative incremental costs against the incremental effectiveness. And when we think about incremental costs, we think not just about systemic therapy or whether you see a physician, but also about hospitalizations, about all the healthcare interactions related to oncology or not that a patient might experience during their time or interactions with the healthcare system. You can imagine with oncology, there are multiple interactions over a prolonged time period depending on survival. And so what we try to do is we try to—and the benefit of the single-payer healthcare system is what we do is we link all those resource utilization patterns that each patient encounters, and we know the price of that encounter. And we compare those incremental costs of, in this case, it's the multigene panel versus the single-gene panel. So it's not just the cost of the panel, not just the cost of systemic therapy, but hospitalizations, physician encounters, etc. And then similarly, we look at, in this case, we looked at overall survival - we can also look at progression-free survival - and ask the simple question, you know, what is the incremental cost per life-year gained? And in that way, we get a metric or an understanding of value for money. And how we evaluate that within a deliberative priority setting context is we look at safety and efficacy first. So a regulatory package that you might get from, in our case, Health Canada or the FDA, so we look at that package, and we deliberate on, okay, is it safe and is it effective? How many patients are affected, etc. And then separately, what is the cost-effectiveness? And at what price, if it's not cost-effective, at what price would it be cost-effective? Okay, so for example, we have this metric called the incremental cost-effectiveness ratio, which is incremental cost in the numerator, and in this case, life-years gained in the denominator. And if it is around $50,000 or $100,000 per life-year gained—so if it's in that range, this ratio—then we might say it's cost-effective. If it's above this range, which is common in oncology, especially when we talk about ICIs, etc., then you might want to negotiate a price. And indeed, when we negotiate that price, we use the economic evaluation, that incremental cost-effectiveness ratio, as a way to understand at what price should we negotiate to in order to get value for money for the healthcare system. Dr. Rafeh Naqash:Thank you for explaining those very interesting terminologies. Now, one question I have in the context of what you just mentioned is, you know, like the drug development space, you talked about efficacy and safety, but then on the safety side, we talk about all-grade adverse events or treatment-related adverse events—two different terminologies. From a healthcare utilization perspective, how do you untangle if a patient on a BRAF therapy got admitted for a hypoxic respiratory failure due to COPD, resulting in a hospitalization from the cost, overall cost utilization, or does it not matter? Dr. Dean Regier:We try to do as much digging into those questions as possible. And so, this is real-world data, right? Real-world data is not exactly as clean as you'd get from a well-conducted clinical trial. And so what we do is we look at potential adverse event, whether it's hospitalization, and the types of therapies around that hospitalization to try- and then engage with clinicians to try to understand or tease out the different grades of the adverse event. Whether it's successful or not, I think that is a real question that we grapple with in terms of are we accurate in delineating different levels of adverse events? But we try to take the data around the event to try to understand the context in which it happens. Dr. Rafeh Naqash:Thank you for explaining that, Dean. So, again to the results of this manuscript, could you go into the methodology briefly? Believe you had 147 patients, 147 patients in one arm, 147 in the other. How did you split that cohort, and what were some of the characteristics of this cohort? Dr. Dean Regier:So, the idea, of course, is that we have selection criteria, study inclusion criteria, which included in our case 364 patients. And these were patients who had advanced melanoma within our study time period. So that was 2016 to 2018. And we had one additional year follow. So we had three total years. And what we did is that we linked our data, our healthcare system data. During this time, because the policy change was in 2016, we had patients both go on the multigene panel and on the single-gene BRAF testing. So, the idea was to emulate a pragmatic randomized controlled trial where we looked at contemporaneous patients who had multigene panel testing versus single-gene BRAF testing. And then we did a matching procedure—we call it genetic matching. And that is a type of matching that allows us to balance covariates across the patient groups, across the multigene versus BRAF testing cohorts. The idea again is, as you get in a randomized controlled trial, you have these baseline characteristics that look the same. And then the hope is that you address any source selection or confounding biases that prohibit you to have a clean answer to the question: Is it effective or cost-effective? So you address all those biases that may prohibit you to find a signal if indeed a signal is there. And so, what we did is we created—we did this genetic matching to balance covariates across the two cohorts, and we matched them one-to-one. And so what we were able to do is we were able to find, of those 364 patients in our pool, 147 in the multigene versus 147 in the single-gene BRAF testing that were very, very similar. In fact, we created what's called a directed acyclic graph or a DAG, together with clinicians to say, “Hey, what biases would you expect to have in these two cohorts that might limit our ability to find a signal of effectiveness?” And so we worked with clinicians, with health economists, with epidemiologists to really understand those different biases at play. And the genetic matching was able to match the cohorts on the covariates of interest. Dr. Rafeh Naqash:And then could you speak on some of the highlights from the results? I know you did survival analysis, cost-effectiveness, could you explain that in terms of what you found? Dr. Dean Regier:We did two analyses. The intention-to-treat analysis is meant to emulate the pragmatic randomized controlled trial. And what that does is it answers the question, for all those eligible for multigene or single-gene testing: What is the cost-effectiveness in terms of incremental life-years gained and incremental cost per life-years gained? And the second one was around a protocol analysis, which really answered the question of: For those patients who were actually treated, what was the incremental effectiveness and cost-effectiveness? Now, they're different in two very important ways. For the intention-to-treat, it's around population questions. If we gave single-gene or multigene to the entire population of advanced melanoma patients, what is the cost-effectiveness? The per-protocol is really around that clinical question of those who actually received treatment, what was the incremental cost and effectiveness? So very different questions in terms of population versus clinical cost and effectiveness. So, for the intention-to-treat, what we found is that in terms of life-years gained is around 0.22, which is around 2.5 months of additional life that is afforded to patients who went through the multigene panel testing versus the single-gene testing. That was non-statistically significant from zero at the 5% level. But on average, you would expect this additional 2.5 months of life. The incremental costs were again non-statistically significant, but they're around $20,000. And so when we look at incremental cost-effectiveness, we can also look at the uncertainty around that question, meaning what percentage of incremental cost-effectiveness estimates are likely to be cost-effective at different willingness-to-pay thresholds? Okay? So if you are willing to pay $100,000 to get one gain of life-years, around 52.8% of our estimates, in terms of when we looked at the entire uncertainty, would be cost-effective. So actually that meets the threshold of implementation in our healthcare system. So it's quite uncertain, just over 50%. But what we see is that decision-makers actually have a high tolerance for uncertainty around cost-effectiveness. And so, while it is uncertain, we would say that, well, the cost-effectiveness is finely balanced. Now, when we looked at the population, the per-protocol population, those folks who just got treatment, we actually have a different story. We have all of a sudden around 4.5 or just under 5 months of life gained that is statistically significantly different from zero, meaning that this is a strong signal of benefit in terms of life-years gained. In terms of the changes in costs or the incremental costs, they are larger again, but statistically insignificant. So the question now is, to what extent is it cost-effective? What is the probability of it being cost-effective? And at the $100,000 per life-year gained willingness-to-pay, there was a 73% chance that multigene panel testing versus single-gene testing is cost-effective. Dr. Rafeh Naqash:So one of the questions I have here, this is a clarification both for myself and maybe the listeners also. So protocol treatment is basically if you had gene testing and you have a BRAF in the multigene panel, then the patient went on a BRAF treatment. Is that correct? Dr. Dean Regier:It's still physician choice. And I think that's important to say that. So typically what we saw in both in our pre- and post-matching data is that we saw around 50% of patients, irrespective of BRAF status, get an ICI, which is appropriate, right? And so the idea here is that you get physician-guided care, but if the patient no longer performs on the ICI, then it gives them a little bit more information on what to do next. Even during that time when we thought it wasn't going to be common to do an ICI, but it was actually quite common. Dr. Rafeh Naqash:Now, did you have any patients in this study who had the multigene testing done and had an NRAS or a KIT mutation and then went on to those therapies, which were not captured obviously in the single-gene testing, which would have just tried to look at BRAF? Dr. Dean Regier:So I did look at the data this morning because I thought that might come up in terms of my own questions that I had. I couldn't find it, but what we did see is that some patients went on to clinical trials. So, meaning that this multigene panel testing allowed, as you would hope in a learning healthcare system, patients to move on to clinical trials to have a better chance at more appropriate care if a target therapy was available. Dr. Rafeh Naqash:And the other question in that context, which is not necessarily related to the gene platform, but more on the variant allele frequency, so if you had a multigene panel that captured something that was present at a high VAF, with suspicion that this could be germline, did you have any of those patients? I'm guessing if you did, probably very low number, but I'm just thinking from a cost-effective standpoint, if you identify somebody with germline, their, you know, first-degree relative gets tested, that ends up, you know, prevention, etc. rather than somebody actually developing cancer subsequently. That's a lot of financial gains to the system if you capture something early. So did you look at that or maybe you're planning to look at that? Dr. Dean Regier:We did not look at that, but that is a really important question that typically goes unanswered in economic evaluations. And so, the short answer is yes, that result, if there was a germline finding, would be returned to the patient, and then the family would be able to be eligible for screening in the appropriate context. What we have found in economic evaluations, and we've recently published this research, is that that scope of analysis is rarely incorporated into the economic evaluation. So those downstream costs and those downstream benefits are ignored. And when you- especially also when you think about things like secondary or incidental findings, right? So it could be a germline finding for cancer, but what about all those other findings that we might have if you go with an exome or if you go with a genome, which by the way, we do have in British Columbia—we do whole-genome and transcriptome sequencing through something called the Personalized OncoGenomics program. That scope of evaluation, because it's very hard to get the right types of data, because it requires a decision model over the lifetime of both the patients and potentially their family, it becomes very complicated or complex to model over patients' and families' lifetime. That doesn't mean that we should not do it, however. Dr. Rafeh Naqash:So, in summary Dean, could you summarize some of the known and unknowns of what you learned and what you're planning in subsequent steps to this project? Dr. Dean Regier:Our North Star, if you will, is to really understand the entire system effect of next-generation sequencing panels, exome sequencing, whole genomes, or whole genomes and transcriptome analysis, which we think should be the future of precision oncology. The next steps in our research is to provide a nice base around multigene panels in terms of multigene versus single-gene testing, whether that be colorectal cancer, lung cancer, melanoma, etc., and to map out the entire system implications of implementing next-generation sequencing panels. And then we want to answer the questions around, “Well, what if we do exomes for all patients? What if we do whole genomes and transcriptomes for all patients? What are the comparative outcomes for a true tumor-agnostic precision oncology approach, accounting for, as you say, things like return of results with respect to hereditary cancers?” I think the challenge that's going to be encountered is really around the persistent high costs of something like a whole-genome and transcriptome sequencing approach. Although we do see the technology prices going down—the "$1,000 genome" or “$6,000 genome" on whatever Illumina machine you might have—that bioinformatics is continuing to be expensive. And so, there are pipelines that are automated, of course, and you can create a targeted gene report really rapidly within a reasonable turnaround time. But of course, for secondary or what I call level two analysis, that bioinformatics is going to continue to be expensive. And so, we're just continually asking that question is: In our healthcare system and in other healthcare systems, if you want to take a precision oncology approach, how do you create the pipelines? And what types of technologies really lend themselves to benefits over and above next-generation sequencing or multigene panels, allowing for access to off-label therapies? What does that look like? Does that actually improve patients? I think some of the challenges, of course, is because of heterogeneity, small benefiting populations, finding a signal if a signal is indeed there is really challenging. And so, what we are thinking through is, with respect to real-world evidence methods and emulating randomized controlled trials, what types of evidence methods actually allow us to find those signals if indeed those signals are there in the context of small benefiting populations? Dr. Rafeh Naqash:Thank you so much, Dean. Sounds like a very exciting field, especially in the current day and age where cost-effectiveness, financial toxicity is an important aspect of how we improve upon what is existing in oncology. And then lots more to be explored, as you mentioned. The last minute and a half I want to ask about you as an individual, as a researcher. There's very few people who have expertise in oncology, biomarkers, and health economics. So could you tell us for the sake of our trainees and early career physicians who might be listening, what was your trajectory briefly? How did you end up doing what you're doing? And maybe some advice for people who are interested in the cost of care, the cost of oncology drugs - what would your advice be for them very briefly? Dr. Dean Regier:Sure. So I'm an economist by training, and indeed I knew very little about the healthcare system and how it works. But I was recruited at one point to BC Cancer, to British Columbia, to really try to understand some of those questions around costs, and then I learned also around cost-effectiveness. And so, I did training in Scotland to understand patient preferences and patient values around quality of care, not just quantity of life, but also their quality of life and how that care was provided to them. And then after that, I was at Oxford University at the Nuffield Department of Population Health to understand how that can be incorporated into randomized control trials in children. And so, I did a little bit of learning about RCTs. Of course, during the way I picked up some epidemiology with deep understanding of what I call econometrics, what others might call biostatistics or just statistics. And from there, it was about working with clinicians, working with epidemiologists, working with clinical trialists, working with economists to understand the different approaches or ways of thinking of how to estimate efficacy, effectiveness, safety, and cost-effectiveness. I think this is really important to think through is that we have clinical trialists, we have people with deep understanding of biostatistics, we have genome scientists, we have clinicians, and then you add economists into the mix. What I've really benefited from is that interdisciplinary experience, meaning that when I talk to some of the world's leading genome scientists, I understand where they're coming from, what their hope and vision is. And they start to understand where I'm coming from and some of the tools that I use to understand comparative effectiveness and cost-effectiveness. And then we work together to actually change our methods in order to answer those questions that we're passionate about and curious about better for the benefit of patients. So, the short answer is it's been actually quite a trajectory between Canada, the UK. I spent some time at the University of Washington looking at the Fred Hutch Cancer Research Center, looking at precision oncology. And along the way, it's been an experience about interdisciplinary research approaches to evaluating comparative outcomes. And also really thinking through not just at one point in time on-off decisions—is this effective? Is it safe? Is it cost-effective?—not those on-off decisions, but those decisions across the lifecycle of a health product. What do those look like at each point in time? Because we gain new evidence, new information at each point in time as patients have more and more experience around it. And so what really is kind of driving our research is really thinking about interdisciplinary approaches to lifecycle evaluation of promising new drugs with the goal of having these promising technologies to patients sooner in a way that is sustainable for the healthcare system. Dr. Rafeh Naqash:Awesome. Thank you so much for those insights and also giving us a sneak peek of your very successful career. Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. Thank you. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Liz Gunn discusses the recent Canadian election with Dr. Mark Trozzi and writer Matthew Pauly, addressing the constitutional crisis and exploring the critical next steps in confronting Globalist agendas.Links: - Dr Mark Trozzi MD on X/Twitter: https://x.com/DrTrozzi- Matthew Pauly on X: https://x.com/MatthewPauly13- World Council for Health Canada film - https://www.wchcanada.news/p/a-canadian-story- Globalist Banker Jacques Attali in 1981 | Liz Gunn Reads: https://rumble.com/v644uzm-globalist-banker-jacques-attali-in-1981-liz-gunn-reads.html?e9s=src_v1_ucp--------FreeNZ:https://freenz.carrd.co

Are you new to the medical device industry—or mentoring someone who is? In this foundational episode of the Global Medical Device Podcast, host Etienne Nichols sits down with Sara Adams and Chris Rush from Greenlight Guru to deliver a MedTech 101 masterclass. They unpack the roles, regulations, and realities of medical device development in a heavily regulated space. From defining what actually counts as a medical device to navigating FDA classifications and global regulations, the trio offers practical insights, industry analogies, and personal war stories that make this episode as entertaining as it is educational. Whether you're in R&D, marketing, clinical, or quality, this is the episode to bookmark and share with every new hire.Key Timestamps02:20 – What counts as a medical device? Intended use and labeling06:48 – Differentiating roles: Quality, Regulatory, Clinical, R&D, and Marketing15:40 – Understanding regulatory bodies: FDA, EU MDR, Health Canada, and more20:15 – FDA Classifications: Class I, II, III, and what determines risk26:00 – Standards to know: ISO 13485, 14971, 14155, 21 CFR Part 82033:05 – FDA pathways: 510(k), De Novo, PMA – when and why they apply41:55 – The design control matrix explained (User Needs through Validation)49:00 – Reverse engineering design controls: pitfalls and best practices55:30 – Clinical trials vs. preclinical studies: When each is required1:00:45 – Manufacturing & supplier controls: operations meets compliance1:04:15 – Final advice for MedTech newcomers: Read the regs and know the problemQuotes“Just because you don't call it a medical device doesn't mean the FDA agrees with you.” – Sarah AdamsThis quote highlights a key regulatory pitfall: your marketing claims, not just your label, determine if the FDA considers your product a medical device.“A 510(k) is like someone checking your wristband at the door—you're cleared to go in. A PMA? That's a locked door and you need full approval to enter.” – Chris RushA memorable analogy that demystifies the difference between FDA clearance and approval pathways.Top TakeawaysLabeling + Intended Use = Regulatory TriggerWhether it's software or a simple tool, if your product makes medical claims or supports medical decision-making, it may fall under FDA or other international regulatory oversight.Regulatory Pathways Are Tied to Risk and NoveltyKnow the difference between a 510(k), De Novo, and PMA. Class II “me-too” devices may avoid clinical trials, while Class III and novel devices usually require significant evidence.Understand Design Controls EarlyReverse-engineering documentation late in development is risky and inefficient. Start early with user needs and build forward through the five pillars: inputs, outputs, verification, and validation.Cross-functional Understanding Prevents Compliance GapsMarketing, clinical, and R&D all influence regulatory standing. Even social media likes can trigger off-label scrutiny—every department needs to understand their regulatory impact.Reading Regulations Is Not OptionalA strong regulatory foundation is key to faster development, better audits, and smoother market access. Resources like 21 CFR Part 820 and ISO 13485 are surprisingly readable and essential.References & ResourcesEtienne Nichols on LinkedInChris Rush on LinkedIn

I have a special in-house interview today with 2 men currently on a mission across Canada sharing the truth about a story of a family and their plight to help those suffering with mental illness and about the nightmare this family had to endure for years.Todd Michael Harris and David Stephan are on tour promoting the film 'Epiphany' and David's harrowing journey. The interview delves deeply into David's family's struggles with mental health, their pioneering work in nutritional supplements, and an intense legal battle with the Canadian health system.They discuss the transformative power of their line supplements, aptly named True Hope, the dynamics behind David's wrongful conviction, the death of his son Ezekiel, and how media and health authorities continue to misrepresent their story despite clear proof otherwise.This is a story of resilience and highlights the corruption among organizations we look to for justice, truth and support. Instead of finding any of these things, the Stephans were met with corruption at every step that started over 20 years ago.Please go to Matadorfilms.ca to see if this film and discussion is coming to your city in the next few weeks. This is a story that needs to be told, heard and shared.01:00 Introducing Today's Special Guests: Todd Michael Harris and David Stephan01:29 The Tragic Story of David Stephan's Family03:48 Todd's Journey in Filmmaking06:03 David's Family History and Struggles with Mental Health15:13 The Birth of True Hope and Nutritional Discoveries28:56 The Impact of Health Canada and Legal Battles34:13 The Fight for Truth and Justice37:51 The Power of Justice and Identity38:26 Reaching Beyond the Choir38:41 Challenges in Spreading the Truth39:01 Audience Reactions and Support41:25 The Birth of True Hope Empire Plus43:23 Health Canada's Contradictions44:13 Justice and Truth: An Interdependent Relationship45:22 Media's Role in Shaping Public Perception47:40 Medical Misadventures and Systemic Issues49:47 The Fight for Natural Health Products50:56 Legal Battles and Personal Struggles52:25 The Aftermath and Seeking Justice56:05 Systemic Corruption and Cover-Ups01:04:44 Exposing the Truth and Seeking Accountability01:07:25 Personal Connections and Accountability01:07:55 The Illusion of Trust in Systems01:08:48 Facing Challenges and Integrity01:09:25 The Plea Bargain Dilemma01:11:40 Tour Goals and Media Coverage01:17:43 Nutritional Products and Their Benefits01:25:05 Protocols and Health Canada Restrictions01:30:33 Final Thoughts and Call to ActionPlease share this interview, the world needs to know the truth about the nightmare this family has experienced at the hands of authorities that people wrongfully trust.If you enjoyed this episode, please share and consider going to www.sovereigncollective.org/shop to check out my offerings and get a deal while supporting the podcast. I'll be adding more great offerings there over time.To find out more about David Stephan and True Hope:Website: https://www.truehope.com/Facebook: https://www.facebook.com/david.stephan.568Instagram: https://www.instagram.com/stand4truth.ca/To find out more about the films of Todd Michael Harris:https://matadorfilms.ca/Please like and subscribe wherever you listen... it all helps and I appreciate it with my whole heart!----------------------------------------------------------Are you concerned about the future of our children?The world needs more conscious parents. Stop raising children who need to recover from their childhoods! Get your online program chock full of interviews with world renowned experts here:http://www.sovereigncollective.org/gettheguideEmail me: sascha at sovereigncollective dot org

Dr. Mark Ware joins Chris to discuss the state of the science for medical cannabis. Why should we be calling it cannabis and not marijuana? What are the challenges of studying something that is still illegal in the United States? How good is it at treating chronic pain and which of its health claims are mainly hype?  Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information.

Some people struggling with opioid addiction are turning to a powerful psychedelic called ibogaine. The drug is derived from the bark of an African rainforest shrub, and its proponents believe it sends people on a transformative journey that can free them from addiction. In countries like Mexico, ibogaine use is unregulated, so resort-like clinics are offering what they consider treatment for addiction, by sending people on powerful psychedelic trips. In her documentary "Ibogaine: The Last Trip?", senior CBC reporter Karen Pauls introduces us to Rocky Dhillon. He's one of a growing number of Canadians who are seeking out this treatment in Mexico. We'll also meet a Winnipeg businessman who is trying to get Health Canada approval for clinical trials of ibogaine, with the goal of offering it as a treatment for addiction in Canada. Some say the drug has changed their lives but there have also been tragic consequences, like the Canadian man who died on an ibogaine trip in South Africa. Produced by Karen Pauls and Joan Webber / originally aired on The Current. Storylines is part of the CBC Audio Doc Unit

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/This Band willl Blow your Mind! Codex Serafini: https://codexserafini.bandcamp.com/album/the-imprecation-of-animaRev. Dr. Jessica Rochester is the Madrinha and President of Céu do Montréal, a Santo Daime (Ayahuasca) Church she founded in 1997 in Montréal, Canada.She is a transpersonal counselor, she trained in the work of Dr. Roberto Assagioli and trained with Dr. Stanislav Grof.She worked with Health Canada from 2000 until 2017 to achieve an Section 56 Exemption to import and serve the Santo DaimeSacrament (Ayahuasca).She is an ordained Interfaith Minister with a Doctorate in Divinity.From 1986 to 2018 she has been a workshop leader, teacher, and in private practice.She is the author of Ayahuasca Awakening A Guide to Self-Discovery, Self-Mastery and Self-Care, Volume One and Two.She continues to lecture on consciousness, non-ordinary states of consciousness, self-discovery, spiritual development, health and well-being and personal transformationhttps://www.revdrjessicarochester.com/https://psychedelicscene.com/2024/06/20/entheogens-psychedelics-nosc-and-the-search-for-wholeness/Self-importance is the veil that wraps the mind in illusions of grandeur—a kingdom built on shifting sands, where the ruler mistakes the walls for the world.Otherness is the doorway disguised as a stranger—an invitation to lose yourself in the eyes of another and find, at last, the ocean beyond the shore. Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/This Band Will Blow Your Mind: Codex Serafinihttps://codexserafini.bandcamp.com/album/the-imprecation-of-anima

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/This Band willl Blow your Mind! Codex Serafini: https://codexserafini.bandcamp.com/album/the-imprecation-of-animaRev. Dr. Jessica Rochester is the Madrinha and President of Céu do Montréal, a Santo Daime (Ayahuasca) Church she founded in 1997 in Montréal, Canada.She is a transpersonal counselor, she trained in the work of Dr. Roberto Assagioli and trained with Dr. Stanislav Grof.She worked with Health Canada from 2000 until 2017 to achieve an Section 56 Exemption to import and serve the Santo DaimeSacrament (Ayahuasca).She is an ordained Interfaith Minister with a Doctorate in Divinity.From 1986 to 2018 she has been a workshop leader, teacher, and in private practice.She is the author of Ayahuasca Awakening A Guide to Self-Discovery, Self-Mastery and Self-Care, Volume One and Two.She continues to lecture on consciousness, non-ordinary states of consciousness, self-discovery, spiritual development, health and well-being and personal transformationhttps://www.revdrjessicarochester.com/https://psychedelicscene.com/2024/06/20/entheogens-psychedelics-nosc-and-the-search-for-wholeness/Self-importance is the veil that wraps the mind in illusions of grandeur—a kingdom built on shifting sands, where the ruler mistakes the walls for the world.Otherness is the doorway disguised as a stranger—an invitation to lose yourself in the eyes of another and find, at last, the ocean beyond the shore. Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/This Band Will Blow Your Mind: Codex Serafinihttps://codexserafini.bandcamp.com/album/the-imprecation-of-anima

Aaron Hefter, CEO of IMARAÏS, joins us to explore the future of beauty through ingestible skincare and wellness. From plant-based, clinically backed formulations to Health Canada certifications, Aaron shares how IMARAÏS is addressing skin concerns, hair loss, and hormonal health from the inside out. We discuss the power of natural ingredients, innovative delivery systems, and why a holistic approach is shaping the next generation of beauty. LINKS:  Shop IMARAÏS here.  Follow IMARAÏS on Instagram, Facebook and TikTok. Learn more about IMARAÏS here.  Discover all things Boutique Skin Envie here.

Episode 201 – we look at how we grew cannabis outdoors – the new regulations from Health Canada our out and we have a window to your weed.  We stop on Cultivar Corner, brought to you by Up In Smoke, we tastes the duo for the live rosin, Purfefire Grape Slurpee and Critical Condition.   All of that more on episode 201 of the Cannabis Potcast.Outdoor cannabisHealth Canada UpdatePurefire Grape Slurpee and Critical Condition

A Canadian adult entertainment company faces an $850,000 fine after Health Canada's undercover operation exposed a lucrative scheme selling "natural health products" that secretly contained prescription medication. Michael Mulligan walks us through how MFH International Enterprises marketed pills called "Harmony" and "Passion Femme" as herbal alternatives while charging premium prices of nearly $140 for just 10 tablets. Health Canada's testing revealed these products contained triple doses of erectile dysfunction medications - putting unwitting consumers at serious risk, especially those with heart conditions.The case raises alarming questions about consumer safety in the natural health product market. As Mulligan points out, "Not everything natural is necessarily good for you," noting that even legitimately natural ingredients with exotic names like "horny goat weed" and "tomcat" deserve scrutiny. The court's substantial fine was carefully calculated to exceed the company's profits while remaining collectible over five years - though Mulligan questions whether corporate shell games might ultimately prevent full payment.The episode also examines a sobering reality about Canada's "not criminally responsible" verdicts. A man found NCR in 2012 for criminal harassment and uttering threats - offences that typically wouldn't result in lengthy prison terms - has now spent twelve years under involuntary psychiatric detention. His case starkly illustrates how NCR findings can lead to indefinite confinement rather than the "get out of jail free card" commonly assumed by the public.Closing with an analysis of British Columbia's proposed Economic Stabilization Act, Mulligan warns about delegating sweeping regulatory powers that bypass legislative debate. The bill would allow the government to rapidly impose tolls, fees, and restrictions through regulation alone - potentially creating chaotic policy shifts similar to what we've seen with international tariffs. While quick responses to economic challenges are appealing, Mulligan cautions that such broad authority demands careful consideration: "We should slow down... if you grant sweeping powers to do things which could seriously impact people's lives and livelihoods, sometimes you're going to cause serious harm."Note: Legally Speaking With Michael Mulligan is now live on CFAX 1070 at 12:30 pm rather than 10:30 am every Thursday. Follow this link for a transcript of the show and links to the cases discussed.

I was very proud to use the word “apotheosis” on today's podcast.  See if you can pick out the moment.  I say something like, “Palliative care for people experiencing homelessness is, in many ways, the apotheosis of great palliative care.”  And I believe that to be true.  When you think about the early concepts that shaped the field, you can see how palliative care for persons experiencing homelessness fits like a hand in a glove: total pain envisioned by Cicely Saunders, which even its earliest sketches included social suffering like loneliness; or Balfour Mount, who coined the term “palliative care,” lamenting the cruel irony of our care for the dying, and the desperate need to create programs to reach more people experiencing suffering. Today we talk with Naheed Dosani, a palliative care physician at St. Michael's Hospital in Toronto, and health justice activist. His story, which he shares on today's podcast, is remarkable.  Just out of fellowship, Naheed built a palliative care program for homeless persons  called the Palliative Education and Care for the Homeless (PEACH) Program.  This podcast is a complement to our prior podcast on aging and homelessness with Margot Kushel. Today we discuss: What is the best terminology? Homeless? Homelessness? Houseless? Marginally housed? What makes palliative care for people experiencing homelessness challenging? What makes it rewarding?  What is unique about the practice of palliative care for people experiencing homelessness? We discuss the principles of harm reduction, social determinants of health, and trauma informed care.  Major overlap with substance use disorder issues, which we have covered recently (and frequently) on this podcast. How are the health systems designed or not designed to meet the needs of people experiencing homelessness?  What are the equity issues at stake, and at risk of being cut, both in Canada and the US?   Many more links below.  And I had a blast playing Blinding Lights by that Toronto band The Weekend. Enjoy! -Alex   End Well Talk https://www.youtube.com/watch?v=eG4QE-hfPQU Resources on the PEACH Program Program Review Paper – A recent publication in Longwoods Healthcare Quarterly reviewing the PEACH model. https://pubmed.ncbi.nlm.nih.gov/37144698/ Promising Practice Recognition – PEACH was named a Promising Practice in equity-oriented palliative care as part of a national initiative funded by Health Canada, operated by Healthcare Excellence Canada & the Canadian Partnership Against Cancer. https://www.healthcareexcellence.ca/media/z3jifqqd/pp-peach-en-2024-v2.pdf Toronto Star Feature https://www.thestar.com/life/together/people/dr-naheed-dosani-started-peach-to-provide-palliative-care-for-homeless-and-vulnerably-housed-populations/article_c56d8f45-cbe9-522e-9554-46778bf50407.html CityNews Toronto Feature https://toronto.citynews.ca/2022/08/08/peach-team-palliative-health-care-homelessness/ Psychosocial Interventions at PEACH In addition to medical care, PEACH also runs two key psychosocial interventions for our clients: PEACH Grief Circles – Structured spaces for workers in the homelessness sector to process grief. CBC covered this a few years ago, including a radio segment feature on CBC White Coat, Black Art (which you can access at the below link). https://www.cbc.ca/radio/whitecoat/palliative-care-team-helps-the-homeless-die-with-dignity-a-healing-circle-helps-them-grieve-1.5048409 PEACH Good Wishes Program – A program that provides meaningful gifts for unhoused individuals who are terminally ill. https://www.cbc.ca/news/canada/toronto/toronto-homeless-palliative-holidays-1.5407360 Kensington Hospice & 'Radical Love' Equity-Oriented Hospice Palliative Care Naheed Dosani also serves as the Medical Director of Kensington Hospice, Toronto's largest hospice. There, he helps run an innovative program called 'Radical Love' Equity-Oriented Hospice Palliative Care, which provides low-threshold, low-barrier access to hospice care for structurally vulnerable individuals (e.g., those experiencing homelessness). The program also operates via a partnership with the PEACH Program. As a result of the 'Radical Love' program at Kensington Hospice: At any given time, Kensington Hospice has evolved from caring for structurally vulnerable individuals

While it is proven to be lifesaving in carbon monoxide poisoning, is there any evidence that hyperbaric oxygen therapy helps with cerebral palsy, autism, long covid, migraines and many other conditions? Can HBOT be both a valid medical therapy and a pseudoscience? Guest co-host Pedro Mendes joins Dr. Chris Labos to parse out fact from fiction. Bonus points if you know the one condition where hyperbaric oxygen therapy is strictly contra-indicated.   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References:   Hyperbaric oxygen therapy – Health Canada https://www.canada.ca/en/health-canada/services/healthy-living/your-health/medical-information/hyperbaric-oxygen-therapy.html   Chris' article on hyperbaric oxygen therapy: https://www.montrealgazette.com/opinion/columnists/article560792.html   Recent child's death https://www.medscape.com/viewarticle/clinic-death-raises-questions-about-oxygen-therapy-2025a10003wa?ecd=wnl_tp10_daily_250216_MSCPEDIT_etid7230220&uac=207389HY&impID=7230220   Trauma Bouachour G, Cronier P, Gouello JP, Toulemonde JL, Talha A, Alquier P. Hyperbaric oxygen therapy in the management of crush injuries: a randomized double-blind placebo-controlled clinical trial. J Trauma. 1996 Aug;41(2):333-9. doi: 10.1097/00005373-199608000-00023. PMID: 8760546.   Burns Brannen AL, Still J, Haynes M, Orlet H, Rosenblum F, Law E, Thompson WO. A randomized prospective trial of hyperbaric oxygen in a referral burn center population. Am Surg. 1997 Mar;63(3):205-8. PMID: 9036884.   Radiation injury Lin ZC, Bennett MH, Hawkins GC, Azzopardi CP, Feldmeier J, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023 Aug 15;8(8):CD005005. doi: 10.1002/14651858.CD005005.pub5. PMID: 37585677; PMCID: PMC10426260.   Chronic wounds: Kranke P, Bennett MH, Martyn-St James M, Schnabel A, Debus SE, Weibel S. Hyperbaric oxygen therapy for chronic wounds. Cochrane Database Syst Rev. 2015 Jun 24;2015(6):CD004123. doi: 10.1002/14651858.CD004123.pub4. PMID: 26106870; PMCID: PMC7055586.   Cerebral palsy Collet JP, Vanasse M, Marois P, Amar M, Goldberg J, Lambert J, Lassonde M, Hardy P, Fortin J, Tremblay SD, Montgomery D, Lacroix J, Robinson A, Majnemer A. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. HBO-CP Research Group. Lancet. 2001 Feb 24;357(9256):582-6. doi: 10.1016/s0140-6736(00)04054-x. PMID: 11558483.  

Seed-starting season has officially begun! This week on Down the Garden Path podcast, Joanne Shaw gets tips and advice on seeds for your lawn and garden from Rebecca Boyar of West Coast Seeds. About Rebecca Boyar  Rebecca Boyar has an extensive and varied career in horticulture, spanning nearly 35 years. She began her journey managing an herb farm on the west coast in the early 90s. From there, she transitioned to developing a non-profit horticultural program and launching the first urban hydroponic training facility in Canada. She later worked as a Non-GMO Commodity Merchandiser at a small agricultural brokerage in southern Manitoba, focusing on soybean and organic production. In 2018, she moved into the cannabis sector, serving as a Master Grower and a Health Canada approved Quality Assurance Processor in Quebec. Currently, Rebecca is a West Coast Seeds representative in eastern Ontario, offering her horticultural expertise and knowledge in the non-GMO and organic seeds market. About West Coast Seeds West Coast Seeds was founded in 1983 in Vancouver, British Columbia, with the purpose of sourcing and supplying seeds of the highest quality while following the traditions of organic farming and gardening. They offer over 1,100 varieties of untreated, non-genetically modified seeds. For them, organic is about much more than saying no to chemicals, it is about saying yes to building a healthy soil for the future. Renee's Garden and Cornucopia Seeds are sister brands of West Coast Seeds, proudly owned and operated by the same Canadian-based family. You can find these premium-quality seeds at garden centres across Canada. Here are some of the topics covered in this episode: Rebecca discussed her journey to West Coast Seeds and how the season of seed starting is upon us. Provided tips on the seeds that need an early start and that we should start now. The new seed mix from West Coast Seeds called Grub Resistant Lawn Blend. Regular turf attracts grubs, which affects our lawns, leading to Japanese beetles, which affect our plants. This new mix of Tall Fescue and pelleted Micro-Clover forms a thick, drought-resistant lawn without the thatch that the beetles love to lay their eggs in. Rebecca discussed the best practices for applying this grass seed and there is more information on their website. West Coast Seeds has a nice variety of lawn blends for many situations including a Chafer Beetle Resistant lawn blend for those that battle the Chafer Beetle and an Alternative Lawn Wildflower mix. This blend is an alternative to having a lawn, and it forms low-growing ground cover that includes a mix of fine fescues, flowers and clover species that stay about 6-8 inches high. A nice idea for anyone with a small lawn who wants to support pollinators. You can order seed from their website or most garden centres will stock West Coast Seeds. If you cannot find something you want in a local store then you can request the store to order it for you. For those that enjoy a paper seed catalog, you can order one from their website, as well. Find West Coast Seeds online: Website: www.westcoastseeds.com Instagram: @westcoastseeds Facebook: @westcoastseeds  ouTube: @westcoastseedstv Have a topic you'd like Joanne to discuss? Email your questions and comments to downthegardenpathpodcast@hotmail.com, or connect via her website at down2earth.ca Find Down the Garden Path on Instagram, Facebook, and YouTube: @downthegardenpathpodcast. Down the Garden Path Podcast On Down The Garden Path, professional landscape designer Joanne Shaw discusses down-to-earth tips and advice for your plants, gardens and landscapes. As the owner of Down2Earth Landscape Design, Joanne Shaw has been designing beautiful gardens for homeowners east of Toronto for over a decade. She does her best to bring you interesting, relevant and useful topics to help you keep your garden as low maintenance as possible.  In Down the Garden Path: A Step-By-Step Guide to Your Ontario Garden, Joanne and fellow landscape designer Matthew Dressing distill their horticultural and design expertise and their combined experiences in helping others create and maintain thriving gardens into one easy-to-read monthly reference guide. Get your copy today on Amazon. Don't forget to check out Down the Garden Path on your favourite podcast app and subscribe! You can now catch the podcast on YouTube.

Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USBuy Grow kit: https://modernmushroomcultivation.com/Rev. Dr. Jessica Rochester is the Madrinha and President of Céu do Montréal, a Santo Daime (Ayahuasca) Church she founded in 1997 in Montréal, Canada.She is a transpersonal counselor, she trained in the work of Dr. Roberto Assagioli and trained with Dr. Stanislav Grof.She worked with Health Canada from 2000 until 2017 to achieve an Section 56 Exemption to import and serve the Santo DaimeSacrament (Ayahuasca).She is an ordained Interfaith Minister with a Doctorate in Divinity.From 1986 to 2018 she has been a workshop leader, teacher, and in private practice.She is the author of Ayahuasca Awakening A Guide to Self-Discovery, Self-Mastery and Self-Care, Volume One and Two.She continues to lecture on consciousness, non-ordinary states of consciousness, self-discovery, spiritual development, health and well-being and personal transformationhttps://www.revdrjessicarochester.com/https://psychedelicscene.com/2024/06/20/entheogens-psychedelics-nosc-and-the-search-for-wholeness/ Support the show:https://www.paypal.me/Truelifepodcast?locale.x=en_USCheck out our YouTube:https://youtube.com/playlist?list=PLPzfOaFtA1hF8UhnuvOQnTgKcIYPI9Ni9&si=Jgg9ATGwzhzdmjkgGrow your own:https://modernmushroomcultivation.com/

How do we define “Craft Cannabis” in Canada? Greencraft Cannabis, a local Manitoba grow operation, is out to answer this question. Eric Greening discusses the process of obtaining his Health Canada micro cultivation licence and how his new company will grow smaller batches putting the plant first. Not only has Health Canada created opportunity for smaller craft growers to finally legally enter the cannabis space, these new licences have also fashioned economic development opportunities for rural communities. Kirk and Trevor question whether the path craft cannabis businesses follow will be similar to the craft beer industry? They ponder how large growers will compete with this new craft market place. This episode marks the start of a planned series exploring the question above…Greencraft Cannabis - WebsiteEric Greening- LinkedInMusic by:David Crosby - Glory - YouTube(Yes we got a SOCAN membership to use this song all legal and proper like)Additional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

In this week's episode, we bring you the latest cannabis headlines from around the world: Macky leads a tribute to Twisted, honouring a valued community member. Two serving British Armed Forces members admit to attempting to sell cannabis, raising questions about drug policies in the military. (Source: UK News) Margaret explores the growing popularity of cannabis-infused drinks, as more consumers look for alternatives to alcohol. Health Canada releases its first results from cannabis data gathering, shedding light on trends and usage patterns in the country. Billy covers Spain's biggest cannabis B2B event, ICBC, returning to Barcelona, with insights into industry trends, networking, and exclusive discounts. John follows up on last week's story: The U.S. confirms the release of a national detained in Russia on drug charges. (Source: BBC News) New research suggests medical marijuana helps mothers be ‘more present parents' and develop stronger, more positive relationships with their children. Join us as we break down these stories and discuss their impact on the cannabis community! Come and join in the discussion about any of these news articles on our cannabis growing forum, Discord server, or any of your favourite social networks. Visit our website for links.  Website: https://highonhomegrown.com Discord: https://discord.gg/sqYGkF4xyQ Youtube: https://www.youtube.com/highonhomegrown Thank you for downloading and listening to our cannabis podcast! I hope you enjoy this episode.

Roz got a new kitten. What is the ideal work week? Toronto Raptors star Gradey Dick wasn't ready for the snow! Health Canada is warning people against using unauthorized sexual enhancement products. Hilarious commercial fail with Shem & Maurie. 

The latest The Food Professor Podcast episode dives deep into the regulatory landscape shaping Canada's natural health product sector. Hosts Michael LeBlanc and Sylvain Charlebois sit down with Aaron Skelton, President and CEO of the Canadian Health Food Association (CHFA), to discuss pressing industry challenges and opportunities.With 82% of Canadians using natural health products, the CHFA is pivotal in advocating for businesses navigating Health Canada regulations, labelling laws, and cost recovery fees. Skelton shares insights into the Save Our Supplements (SOS) campaign, an initiative pushing back against policies that could increase costs and reduce product availability. He emphasizes the need for regulatory balance that fosters innovation while maintaining consumer safety.The conversation also covers the impact of rising tariffs on Canadian manufacturers, making it harder for local brands to compete with international markets. Skelton highlights the urgent need for policies that support domestic food production and streamline interprovincial trade.Shifting gears, the hosts explore consumer trust and transparency in health products. With increased scrutiny over false claims and misleading marketing, third-party certifications like B Corp and Canadian Organic Certification have become crucial in building credibility. Skelton stresses that transparency—not perfection—is key to maintaining consumer confidence.In the news, we touch on Elon's DOGE cuts to the USDA and their potential impact in Canada, Loblaws' multi-billion-dollar investment, the pause in Saskatchewan's canola processing plant, and KFC's surprising corporate relocation from Kentucky to Texas, as well as the state and future of agriculture in the Ukraine and the practical economics of adding hens in your back yard to make your eggs.This episode is packed with insider knowledge on food safety, economic policy, and industry regulation, making it a must-listen for food professionals, policymakers, and consumers interested in the future of Canada's health and wellness sector. The Food Professor #podcast is presented by Caddle. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. Michael LeBlanc is the president and founder of M.E. LeBlanc & Company Inc, a senior retail advisor, keynote speaker and now, media entrepreneur. He has been on the front lines of retail industry change for his entire career. Michael has delivered keynotes, hosted fire-side discussions and participated worldwide in thought leadership panels, most recently on the main stage in Toronto at Retail Council of Canada's Retail Marketing conference with leaders from Walmart & Google. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, CanWest Media, Pandora Jewellery, The Shopping Channel and Retail Council of Canada to his advisory, speaking and media practice.Michael produces and hosts a network of leading retail trade podcasts, including the award-winning No.1 independent retail industry podcast in America, Remarkable Retail with his partner, Dallas-based best-selling author Steve Dennis; Canada's top retail industry podcast The Voice of Retail and Canada's top food industry and one of the top Canadian-produced management independent podcasts in the country, The Food Professor with Dr. Sylvain Charlebois from Dalhousie University in Halifax.Rethink Retail has recognized Michael as one of the top global retail experts for the fourth year in a row, Thinkers 360 has named him on of the Top 50 global thought leaders in retail, RTIH has named him a top 100 global though leader in retail technology and Coresight Research has named Michael a Retail AI Influencer. If you are a BBQ fan, you can tune into Michael's cooking show, Last Request BBQ, on YouTube, Instagram, X and yes, TikTok.Michael is available for keynote presentations helping retailers, brands and retail industry insiders explaining the current state and future of the retail industry in North America and around the world.

NOTE: An earlier version of this episode said that Germany was one of the countries that had said it would send peacekeeping soldiers to Ukraine. This was wrong. Germany has not said that.World news in 7 minutes. Tuesday 18th February 2025.Today: Ukraine peace meetings. Vatican City Pope health. Canada plane flip. Brazil illegal logging. South Africa gay imam. Sudan aid request. Singapore politician lies. South Korea actress dies. And UK BAFTAs.   With Ben MallettSEND7 is supported by our amazing listeners like you.Our supporters get access to the transcripts written by us every day.Our supporters get access to an English worksheet made by us once per week.Our supporters get access to our weekly news quiz made by us once per week.We give 10% of our profit to Effective Altruism charities.You can become a supporter at send7.org/supportContact us at podcast@send7.org or send an audio message at speakpipe.com/send7Please leave a rating on Apple podcasts or Spotify.We don't use AI! Every word is written and recorded by us!Since 2020, SEND7 (Simple English News Daily in 7 minutes) has been telling the most important world news stories in intermediate English. Every day, listen to the most important stories from every part of the world in slow, clear English. Whether you are an intermediate learner trying to improve your advanced, technical and business English, or if you are a native speaker who just wants to hear a summary of world news as fast as possible, join Stephen Devincenzi, Ben Mallett and Juliet Martin every morning. Transcripts, worksheets and our weekly world news quiz are available for our amazing supporters at send7.org. Simple English News Daily is the perfect way to start your day, by practising your listening skills and understanding complicated stories in a simple way. It is also highly valuable for IELTS and TOEFL students. Students, teachers, TEFL teachers, and people with English as a second language, tell us that they use SEND7 because they can learn English through hard topics, but simple grammar. We believe that the best way to improve your spoken English is to immerse yourself in real-life content, such as what our podcast provides. SEND7 covers all news including politics, business, natural events and human rights. Whether it is happening in Europe, Africa, Asia, the Americas or Oceania, you will hear it on SEND7, and you will understand it.For more information visit send7.org/contact or send an email to podcast@send7.org

When a government releases 300 pages of audits only minutes before a press conference, everyone knows they have something to hide. In Episode 6 we dive into the details, and tell you just how much of a failure the NDP's health care reforms have been with front-line staff.Part 1-“If the disease in our health-care system is a culture of dysfunction, then the symptom of that disease is fiscal mismanagement.”- Manitoba Health Minister Uzoma Asagwara on Wednesday.If anyone's an expert on dysfunction and fiscal mismanagement, it's the Manitoba NDP.You'll hear a few of the unmentioned costs rung up by Shared Health, who the NDP expects you to trust to turn that ship around, and a budget preparation model proposed by the auditors that for some reason isn't good enough for Winnipeg councillors.21.05- Part 2-"After years of losing nurses in Manitoba, we've … started to turn the corner."- Premier Wab Kinew on Friday.That's exceptionally wishful thinking. You'll hear why around that corner, is a cliff. And the NDP has 481 new passengers- em, newly hired nurses - being driven off it.As reported in The Black Rod, a survey of nurses by the union revealed that only 1% of members agreed the Kinew/Asagwara "listening tours" scored an A for responding to what they heard needs fixing.The survey results also show a startling number of nurses"reconsider(ed) how long you anticipate remaining in your nursing career".From workload to workplace violence, the results add up to a solid F - despite the earnest pro-NDP stance of union management.Nurses on the front lines aren't willing to suffer in silence. An MNU Instagram post in January hints that the problem is with the double-dribbling point guard Kinew expects to lead the team."Manitobans need transparency. Manitobans need action." Can Kinew convince Manitobans they need Asagwara? He may have to convince himself first.See also-https://winnipegsun.com/opinion/gold-no-wonder-nurses-quit-really-sick-go-to-the-er-at-your-own-risk******In the Winnipeg Sun on Sunday- my discussion about the proposed drug user site in Point Douglas with a federal official revealed the feds had a little problem with NDP Addictions Minister Bernadette Smith and CBC. And, a day care parent has a problem with a gap in the Health Canada guidelines for public consultations that Smith and the proponents of the site might be taking advantage of.******The Season Six funding campaign has received our first contribution, even before we kicked it off!Your support, whether it's for $100, more, or less, all counts towards ensuring this platform can continue to deliver the analysis, information and interviews you need to know- with no Tru-dough!Our ⁠⁠Donate page⁠ ⁠on ActionLine.ca lists our Top Podcasts of 2024; interviews with political leaders, public figures and crime victims; and reports on City Hall and the Legislature. It includes links for PayPal and E-transfer donations!

Why did the FDA ban the use of Red Dye No. 3 and why is it still available in Canada? Pedro joins Chris to talk about why this happened and how we should think about food colourings in general. Does the fact that it causes cancer in rats mean anything for human health and what about this ADHD link? Also, there's a Winnie the Pooh reference at the end. Become a supporter of our show today either on Patreon or through PayPal! Thank you!  http://www.patreon.com/thebodyofevidence/  https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE  Email us your questions at thebodyofevidence@gmail.com  Assistant researcher: Aigul Zaripova, MD Editor: Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer  Obviously, Chris not your doctor (probably). This podcast is not medical advice for you; it is what we call information. References: The FDA announcement https://www.fda.gov/industry/color-additives/fdc-red-no-3 Study showing a link between Red No. 3 and thyroid cancer in rats https://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.1988.tb01593.x  The link between artificial food colourings and attention deficit hyperactivity disorder https://pmc.ncbi.nlm.nih.gov/articles/PMC3441937/  List of approved food colors in Canada https://inspection.canada.ca/en/food-labels/labelling/industry/food-additives/food-colours     

After our reports in the Winnipeg Sun about the haphazard public consultation process for the proposed drug consumption site, Episode 5 focuses on a comparison raised by another Sun columnist. Part 1- Our stories have detailed the limited outreach for the consultations by the NDP government and Aboriginal Health and Wellness Centre, and what the proponents have heard from Point Douglas and East Exchange district stakeholders concerned with the potential of even more crime and disorder descending on their neighborhood. The failed narrative of site supporters and the media is that anyone with questions are an enemy of addiction treatment. With the area MLA Bernadette Smith being assigned by Wab Kinew to help fulfill his election promise, residents feel she is in a conflict of interest. Where are city councillors or Mayor Scott Gillingham in this process to represent the community? Absent. Yet the spike of vandalism and break-ins and violence they've suffered was directly connected to former Mayor Brian 'don't arrest the criminals' Bowman, as homeless addicts and illegal riverbank encampments terrorized their neighborhoods 13.10- John Wintrup wrote: "There is a more rigorous and fulsome process outlined by the federal government for siting new cell towers compared to siting new safe consumption sites." Not a lot of people in Winnipeg know anything about the federal telecom tower approval process. It just so happens, Marty Gold is one of them. 17.35 Part 2- A major reason behind concerns about a fair and proper consultation not being conducted is the fact Argyle High School is right across the street. As Wintrup described it: "The public is now considering the compatibility of safe consumption sites within 60 metres of schools — the length of an NHL ice sheet – well within an easy walking distance... Either someone at the provincial government thinks safe consumption sites 200 feet from schools are great, or did not think this through at all." 23.00 - Listen to the audio of Bernadette Smith explaining how 200 Disraeli came to be listed as the address on the application- especially in light of Wintrup's analysis. The Health Canada rules for applications to establish a safe consumption site don't even have a defined radius for notifications of nearby properties, services or political representatives, and what details are to be included. But if this was a communications tower being proposed for 200 Disraeli, it would be vastly different- and better protect the public interest. We have the details of the rules set out by ISED including - a well-defined radius for notification mailings - the information required including why the specific location is best-suited to the proposal, - the stringent timelines for acknowledging and replying to public comments and questions, and for addressing or rectifying concerns - the placement of newspaper ads Another interesting point is that a communications tower is visited perhaps twice a year by one or two technicians for repair, maintenance or installation of a new dish. Almost no traffic results, yet formal municipal concurrence is a requirement. Yet for a site frequented by hundreds of addicts weekly to use drugs- and are allowed to walk out the door- it seems Health Canada has no such sign-off required. Federal rules regulate drug site consultations with less rigour than a cell tower proposed in the middle of farmland. And the NDP knows it. IN THE SUN: Media Cheerleaders Won't Deter Consumption Site Questions ⁠ Fake Consumption Site Consultations Not Fooling Pt. Douglas Stakeholders “Please do not set this up in our neighborhood” Smith told about planned drug site Dishonest Consumption Site Consultations Threat to Bernadette Smith's Political Future Our ⁠Donate page⁠ on ActionLine.ca lists Top Podcasts of 2024; interviews with political leaders, public figures and crime victims; and rCity Hall and Legislature reports. It includes links for PayPal and E-transfer donations!

MONOLOGUE Vindicated: Alberta Exposes the Tyranny of COVID-19 Overreach NEWSMAKER A First Nation that announced its discovery of children's graves at a Residential School has sought tens of millions in federal grants including the cost of building a national shrine at Kamloops  https://www.blacklocks.ca/compensation-topped-40m/  The New Democrats' lone MP east of Ontario has sponsored a petition to boycott all trade with Israel. Québec MP Alexandre Boulerice (centre) earlier described Israel as a “boot crushing a human face. https://www.blacklocks.ca/mp-petitions-to-boycott-israel/   Tom Korski, Managing Editor Blacklock's Reporter https://www.blacklocks.ca OPEN LINES THE HOMESCHOOL ADVISOR The Dependency Trap: Why School Choice Is a False Promise https://www.realcleareducation.com/articles/2024/11/27/the_dependency_trap_why_school_choice_is_a_false_promise_1075087.html   Robert Bortins, CEO of Classical Conversations, helping Christian and Classical Home Schoolers in all fifty states and in thirty foreign countries including Canada. https://classicalconversations.com MONOLOGUE Border Truths: Tom Homan Saves America While Selena Gomez Sobs for Criminals NEWSMAKER Tom Homan, New Border Czar, is heart broken after watching “The War on Truth”  Chris Burgard, is Director of the brand new groundbreaking MINI SERIES The War on Truth. He directed the prescient films “Border” which screened for Congress in 2007, and “Death County and the River of Broken Dreams” that screened for Congress, in 2023. WATCH THE WAR ON TRUTH https://hisglory.tv OPEN LINES BEYOND BIG PHARMA FDA Bans “Cancer Causing” Red Dye #3 Health Canada, nah, not so much… https://www.cspinet.org/cspi-news/red-3-fda-finally-bans-cancer-causing-food-dye  Pam Killeen is a health and wellness coach, co-author of The Great Bird Flu Hoax and the host of the Circadian Reboot with Pam Killeen podcast. https://pamkilleen.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textI sit down with Dr. Ramona Coelho to revisit the complex and controversial topic of Medical Assistance in Dying (MAiD) in Canada. Dr. Coelho shares insights from recent Health Canada and Ontario coroner reports, revealing safety concerns, ethical dilemmas, and the societal failures that lead many to seek MAiD. We discuss cases driven by financial constraints, housing insecurity, and loneliness, and explore how Canada's policies differ from other jurisdictions like California and Europe.

Medical assistance in dying, or MAiD, became legal in Canada in June 2016, but the federal government is looking at ways to improve what the law allows. Right now, Health Canada is doing a survey of Canadians about advance requests for MAiD. As it stands right now, the law does not allow medical assistance in dying to be provided based on an advance request. The person asking for MAID must be able to consent, and they can't ask in advance before they are eligible or want to receive it. We asked Health Canada for an interview about its consultation with Canadians, but the department declined. Helen Long is CEO of Dying with Dignity Canada, which works to improve end-of-life care.

It can be found in some of your favourite candies, baked goods and beverages: red dye no. 3.  The FDA has recently banned the synthetic dye from food (by 2027) and oral medication (by 2028) in the United States, but Health Canada says they won't be following suit. So what's the real danger behind this colour additive compared to others we ingest?Host Melanie Ng takes a deep dive into the research with Dr. Emma Allen-Vercoe, Professor and Canada Research Chair with the Department of Molecular and Cellular Biology at the University of Guelph.  We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Fr. Francis J. Mann who delivered a closing prayer at the 2nd Inauguration of Trump. Michael Knowles on his TV career & Catholic faith. Nicolas Tétrault on leaving Canada to get medical care for his son. 

The U.S. surgeon general has called for cancer warnings on alcohol and Health Canada suggests a maximum of two drinks a week. As Dry January winds down, we ask: How can I cut back or even quit drinking alcohol? Dr. Peter Butt, an addiction medicine specialist and clinical associate professor at the University of Saskatchewan, explains how much alcohol is too much and breaks down how people can cut back.For transcripts of The Dose, please visit: lnk.to/dose-transcripts. Transcripts of each episode will be made available by the next workday. For more episodes of this podcast, click this link.

Health Canada's 5th annual report on medical assistance in dying was released in December, reflecting numbers and demographics from 2023. For the first time, race and Indigenous identity, and disability were measured. For a discussion on who is requesting and receiving MAID, and for what illnesses, we welcome James Downar, Clinical Research Chair in Palliative and End of Life Care, Faculty of Medicine, University of Ottawa; Rebecca Vachon, Program Director of Health at Cardus Canada; zSonu Gaind, a psychiatrist and professor at University of Toronto; and Sandy Buchman, a palliative care doctor working out of North York General Hospital.See omnystudio.com/listener for privacy information.

Now is your chance to weigh in on changes around Medical Assistance In Dying. Rachel Cave speaks with a regional expert for his opinion on a new national survey. The online questionnaire is on the Health Canada website and remains open until February 14th.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Mannkind releases info about it's Afrezza pediatric studies, Dexcom launches AI tech with Stelo, Health Canada approves Tandem/Dexcom G7, diabetes drug may help sleep apnea, an app in development to help drivers with T1D and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Mannkid expects to talk to the FDA about Afrezza inhaled insulin for pediatric approval early in 2025. The company just announced six-month results from its Phase 3 INHALE-1 study of kids aged 4-17 with type 1 or type 2 diabetes comparing either inhaled pre-meal insulin or multiple daily injections (MDI) of rapid-acting insulin analog, both in combination with basal insulin. A 26-week extension phase in which all remaining MDI patients were switched to inhaled insulin is ongoing. HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, there were no differences in lung function parameters between the treatment groups, There were no differences between groups or concerns in other safety measures, including hypoglycemia. https://www.medscape.com/viewarticle/inhaled-insulin-benefits-kids-diabetes-too-2024a1000nex   XX Dexcom announces the use of AI for its Stelo platform. The company says the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo users will start seeing the features this week. The AI is modeled after Google Cloud's Vertex AI and Gemini models. We'll hear more about this in January – Dexcom will be part of a panel at the Consumer Electronics Show about AI and healthcare. BTW this press release is the first time I've seen what seems to be a new slogan for Dexcom – Discover What You're Made Of. https://www.businesswire.com/news/home/20241217011997/en/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing XX Staying with Dexcom, users report that the geofencing issue we reported on seems to be resolved. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn't reinstall or use the app without customer support. With the latest iOS and Android G7 apps, this seems to be resolved. This is according to the folks in the DIY community who first brought it to my attention.   XX Interesting insulin development to watch. Egypt approves EVA Pharma's insulin drug products, which is a collbaration between Eli llly and EVA, an Egyptian company. The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.   Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-egypt-302333269.html     XX Can we add treating sleep apnea to the list of applications for terzepatide? That's the generic for Zepbound and Mounjaro. Phase 3 study shows that 10- and 15-milligram injections of Zepbound "significantly reduced the apnea-hypopnea index" among those who have obesity and moderate-to-severe obstructive sleep apnea. Eli Lilly said there was nearly a 20% reduction in weight among those in the trials. The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. https://www.aol.com/popular-weight-loss-drug-could-131507702.html   XX Health Canada okays Tandem's tslim X2 with Dexcom G7 and G6 making it the first and only insulin pump in Canada that is integrated with both Dexcom sensors. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7's 30-minute sensor warm-up time, faster than any other CGM on the market.3 In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch4 can see their glucose numbers directly from their watch without having to access their pump or smartphone4. Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025.   To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca. https://www.businesswire.com/news/home/20241210731189/en/Tandem-tslim-X2-Insulin-Pump-Now-Compatible-with-Dexcom-G7-CGM-in-Canada XX A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision. Insulet filed a lawsuit in the U.S. District Court for the District of Massachusetts in 2023, claiming EOFlow copied patented components of its Omnipod insulin pumps. In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million.   A federal appeals court later overturned the preliminary injunction, and EOFlow resumed selling its devices in Europe. The company recently defended against a separate injunction filed by Insulet in Europe's Unified Patent Court, according to Korea Biomedical Review, an online English newspaper based in Seoul, South Korea.   The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet's trade secrets.   Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury's verdict.” EOFlow did not immediately respond to a request for comment. https://www.medtechdive.com/news/insulet-eoflow-jury-verdict-patent-lawsuit/734745/ XX A tele-education program for health care providers who treat people with diabetes resulted in significant improvements in patient outcomes, including better blood sugar levels and increased use of medical devices to manage the disease, a University of Florida study finds. Led by researchers in the UF College of Public Health and Health Professions and the UF College of Medicine, the program used the Extension for Community Health Care Outcomes model, which has been adopted worldwide to train clinicians who treat patients with a variety of conditions. Known as Project ECHO, this is one of the first to demonstrate patient benefits for the program in a large, randomized trial. The findings appear in the journal Diabetes Care. https://ufhealth.org/news/2024/clinician-training-program-leads-to-better-outcomes-for-patients-with-diabetes XX New app under development to make driving safer for people with diabetes. Diabetes Driving Pal says it will use CGM data and guide you while you are driving without any annoying alerts. Guidance/suggestions will be on your car dashboard so that you don't have to look at phone and it will be very individualized and actionable. In a study last year, ~70% of people have reported (5% reported accident) to have at least one low blood sugar while driving and most reported that CGM alerts were not enough to protect them. We are hoping to start beta testing in a few months. We are trying to raise the fund to develop this product. We need your support. For more information, please visit: https://lnkd.in/gTDhnDc4 XX I'm also going to link to the top ten most read diabetes and endocrinology stories of 2024 from Medscape. This is almost all GLP-1 related.. and mostly for people with type 2. https://www.medscape.com/viewarticle/icymi-top-10-diabetes-endocrinology-stories-2024-2024a1000n6u?&icd=login_success_email_match_fpf XX That's it for the last In the News of 2024! Don't miss out episode next week with a look ahead to what we're watching in 2025. I'm SS I'll see you back here soon…

It's a big episode today! With information that could be a game changer when it comes to homeopathy, and the supplement industry in general.  I'm  chatting  with Daniel Dereser, the CEO of Boiron Canada. We dive into his journey from a pharmacy student in France to CEO in the natural health industry. Daniel talks about his early experiences with homeopathy, how it changed his perspective, and the growth of Boiron. Then, we explore the challenges and misconceptions surrounding homeopathy, especially in Canada. We also discuss the current regulatory landscape for natural health products and the potential impact of Health Canada's cost recovery program. It's a fascinating discussion on integrative medicine, the importance of informed choices, and how Daniel balances his high-stress role with personal wellness practices.Homeopathics Mentioned that can be found https://www.boiron.ca/en/CamiliaOscillococcinum (Oscillo)Arnica montanaNux vomicaCalendula CreamAconitum NapellusTo help with the changing of Health Canada's Regulations, click HERE to Save Our Supplements.Natural health product regulation in Canada: Natural health product cost recovery - Canada.caNHPs: Save Our Supplements - CHFAAbout Daniel:President and CEO since 2015 of Boiron Canada, the Canadian subsidiary of Boiron Laboratories in France, which recently celebrated its 35th anniversary in Canada, Daniel Dereser has more than 18 years of expertise in the homeopathy industry across France, the USA, and Canada.Graduating with a doctorate in Pharmacy (France), he also has diverse experience in strategic management, sales and marketing strategies, drug production, regulatory affairs, and government relations.Before his official arrival at Boiron Canada, Daniel Dereser, born in Marseille, France, earned his Doctor of Pharmacy degree from the University of the Mediterranean of Aix-Marseilles in 2002. As an internal pharmacist at Solvay, Mr. Dereser began studying management at the École de Management de Lyon (EM Lyon) in 2002, focusing on industrial production management. He obtained his graduate degree from the Institute of Industrial Pharmacy in 2003.That same year, he joined Les Laboratoires Boiron in France as a pharmacist responsible for manufacturing production. In 2004, he moved to the West Coast of the United States, where he became a pharmacist and head of the laboratory at Boiron USA, the American subsidiary of Boiron Laboratories. He also served as a specialist in professional education and as Director of Medical Development for Boiron USA.Additionally, he lectured at the Western University of California, focusing on integrative medicine and homeopathy.Mr. Dereser remained with Boiron USA for over 11 years until 2013. Upon his arrival at Boiron Canada, he joined the team as Director of Medical Development before becoming its current President and CEO.Daniel Dereser sits on the Board of Directors of the Homeopathic Pharmaceutical Association of Canada (HPCA) and is also a member of the Canadian Health Food Association (CHFA). A passionate communicator, he has been involved since 2019 in the Coalition for Homeopathy in Quebec (CPHQ), which promotes and defends homeopathy in Quebec.He actively participates in debates, forums, round tables, and media interviews to positively advance homeopathy and its role in patient well-being within integrative medicine approaches.

This episode I encourage you to join in and help out the Canna Winter clothing drive, we cover some petty squabbles in government, survey says 72 percent cannabis consumers are buying legal, Health Canada facing some funding cuts ,and a Canadian company has acquired High Times. On Cultivar Corner, brought to you by Up in Smoke, we've got some Smallz BB Yoduh up for a taste. No age declinePoliticians trade barbsSeventy two percent buy legalBB Yoduh at Up in SmokeHealth Canada funding cutsIntroduction to twaxing 

In this episode of Hart2Heart, Dr. Mike Hart welcomes Kelsi Sheren back to discuss her advocacy for alternative therapies, including her testimony before government bodies on the benefits of psychedelics for veterans and mental health as a whole. She shares her clinical trial experience with synthetic psilocybin and the challenges in accessing such therapies due to bureaucratic red tape. Kelsi shares the importance of integration in healing, the proper ways to integrate plant medicine, the stigma surrounding men's mental health, and practical tools like breathwork to manage PTSD and anxiety. Guest Bio and Links: Kelsi Sheren is a veteran, author, TEDx speaker, and mental health advocate specializing in alternative therapies for trauma. A passionate coach, Kelsi has also appeared on Jordan B. Peterson's podcast and testified before the Canadian Parliament on emerging treatments for PTSD. Listeners can learn more about Kelsi Sheren at her website, and on IG @kelsie_sheren Show Notes: (0:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart    (0:15) Dr. Hart welcomes returning guest, Kelsi Sheren back to the show (1:00) Kelsi's advocacy for psychedelics (4:30) Exploring the effects of synthetic psilocybin (7:00) Barriers to accessing psychedelic therapies (8:30) "Health Canada was more willing to electrocute me than give me a mushroom." (10:30) Integration and coaching techniques (17:00) Integration techniques  (24:00) “The medicine starts once you say ‘yes'.” (28:00) Challenges and stigmas in mental health (32:00) Addressing masculinity and femininity (37:00) The power of connection and emotional vulnerability (39:30) Listening vs. solution-solving in conversation (43:00) Breathwork and managing PTSD (53:00) Holistic approaches to health (59:00) Final thoughts --- Dr. Mike Hart is a Cannabis Physician and Lifestyle Strategist. In April 2014, Dr. Hart became the first physician in London, Ontario to open a cannabis clinic. While Dr. Hart continues to treat patients at his clinic, his primary focus has shifted to correcting the medical cannabis educational gap that exists in the medical community.  Connect on social with Dr. Mike Hart: Social Links: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

What does the body of evidence say about mold? Or if you're part of the Commonwealth, mould? Some mould can make you sick, especially by triggering allergic symptoms, but beware of people selling you a service to detect mould in your home because there is no established “safe” threshold yet. How can you prevent mould from growing where you live? And how do you take care of it once you've spotted it?   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Assistant researcher: Aigul Zaripova, MD Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris is not your doctor (probably). This podcast is not medical advice for you; it is what we call information.   References: 1) Health Canada's Guide to addressing moisture and mould indoors: https://www.canada.ca/en/health-canada/services/publications/healthy-living/addressing-moisture-mould-your-home.html 2) Guidance for Clinicians on the Recognition and Management of Health Effects Related to Mold Exposure and Moisture Indoors: https://health.uconn.edu/occupational-environmental/wp-content/uploads/sites/25/2015/12/mold_guide.pdf 3) The EPA's Course on mold: https://www.epa.gov/mold/mold-course-chapter-1

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Welcome back to "Ditch the Lab Coat," the podcast where we dive into complex healthcare topics with a scientific and skeptical lens. In this episode, our host Dr. Mark Bonta sits down with Dr. Akash Goel, an esteemed anesthesiologist and pain specialist, to explore the intricate world of chronic pain management.We'll delve into the prevalence of chronic conditions like stenosis, myofascial pain dysfunction, and sacroiliac joint dysfunction, particularly in older adults and women. Dr. Goel sheds light on the challenges of pain assessment and the often-overlooked patient experience of feeling disbelieved by family and caregivers.We'll discuss the limitations of traditional pain scales and the innovative tools reshaping pain treatment, such as quantitative sensory testing and real-time data from wearables. Dr. Goel's pioneering research, including a clinical trial with MDMA and ketamine for chronic pain management, will provide a glimpse into the future of pain therapy.Join us for an engaging conversation that highlights the evolving interface of AI, psychedelics, and psychotherapy in tackling chronic pain. Dr. Bonta and Dr. Goel also touch upon the broader challenges within the healthcare system and the exciting potential of new research and technological advancements. Stay tuned for insights that could change how we understand and treat chronic pain.06:40 - Doctors frequently encounter medically unexplained symptoms.08:57 - Chronic pain is diverse, commonly affecting older women.11:45 - Many patients feel disbelieved when reporting chronic pain.16:45 - Pain-related disability and interference assessed using specific scales.17:42 - Leveraging data to predict and manage chronic pain effectively.23:45 - Psychedelic compounds shown to aid in chronic pain psychotherapy.26:17 - Understanding chronic pain requires grouping patients into subcategories.28:48 - Chronic pain alters the brain and spinal cord's response mechanisms.33:58 - Emphasis on the need for quality placebo-controlled clinical trials to refine approaches.37:49 - Research into safe MDMA dosing and administration frequency.38:41 - 120mg of MDMA produces effects similar to 60mg of Ritalin.43:03 - Psychotherapy improves connection, access, and creates lasting therapeutic impacts.49:12 - Chronic pain's complexities inspire exploration of new treatments.50:16 - Psychedelics enhance psychotherapy, with Dr. Goel's research showing optimism.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I'm going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom's Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure's triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure's triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/   XX Blue Circle Health is expanding it's unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It's paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We've got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It's free and we've got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes.   "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes."   "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly's tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial.   Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I'm going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024.  Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse's mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse.  Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that's part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I'm so grateful for our conversations and that our conversations may have helped her get it out there into a world where it's so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book).   Please, write the book, ride the bike, do the ironman, follow your heart and your dreams.  All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/   Thanks for joining me..

Pete Pearson, 74, is not ready to die. He was diagnosed six years ago with idiopathic pulmonary fibrosis, which has an average survival rate of 2-3 years after diagnosis. He knows he's on borrowed time, and has been dealing with anxiety and depression. That's why he's seeking approval from Health Canada to use psilocybin as part of a treatment called psychedelic-assisted psychotherapy. His son Blake, who is also a family doctor, believes it can help his dad live the rest of his life to the fullest.

This episode has themes of: Health, Metabolic health, mental health, lifestyle, Ozempic, Weight loss drugs, Weight loss, Yerba Mate, PCOS, Fertility, Natural Solutions.READY TO START YOUR FEEL GREAT JOURNEY AT 30% OFF?CLICK HERE: https://ufeelgreat.com/can/en/c/14636BPlease note: The information shared in this podcast is for informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified health provider with any questions you may have regarding a medical condition or treatment. Listening to this podcast does not establish a doctor-patient relationship.Today on the show I have Dr. Harleen Dosanjh & Manvir Dosanjh to discuss the Feel Great System by Unicity that is taking North America by storm and helping to radically heal metabolic dysfunction in an all-natural way with no side effects.This system is Health Canada approved and backed by science.Click here for studies: https://www.unicityscience.org/clinical-validation-studies/ For more information please reach out to me on social media @elisakurylowicz or send me an email at elisa@elisaunfiltered.comFor all other links to all things Elisa Unfiltered go to https://elisaunfilteredcoaching.com

Shawn Buckley is a Canadian constitutional lawyer with 30 years of experience and a proven track record defending more natural health companies against Health Canada than any other lawyer.   Since 2008, Mr. Buckley has been President of the Natural Health Products Protection Association (NHPPA), which is dedicated to protecting Canadians' access to natural health products. Among his many accomplishments, he has served as an expert witness on natural health product regulations and constitutional law in both the House of Commons and the Senate, and was perhaps the sole expert witness opposing Bill C-36 (The Consumer Product Protection Act). He also authored The Charter of Health Freedom, which is proposed legislation that gives natural health products and traditional medicines their own Act. A paper petition in support of The Charter is currently the third largest paper petition, pending delivery, in Canadian history.   Most recently, Mr. Buckley drafted a Private Member's Bill to protect natural product access for all Canadians by amending the Food and Drugs Act (natural health products). With the support of Members of Parliament, the Private Member's Bill is now named Bill C-368 and has passed second reading in the House of Commons. www.truehopecanada.com www.nhppa.org

Christopher James rejoins the program to discuss his battles with Health Canada and Masterpeace. He describes how they are actively trying to keep safe and effective supplements from the public. He also describes the UN Pact for the Future and the WHO amendments. He shares how these two global entities with unelected bureaucrats intend to implement forced vaccinations and internment camps according to their recent documents and signed resolutions.You can follow Christopher James and watch him on his weekly Thursday night shows at https://aWarriorCalls.com

Karen Quatromoni, Director of Public Relations at OMG, introduces the podcast series and its focus on the Digital Twin Consortium (DTC). Bill Hoffman, OMG CEO and Chairman, interviews Doug Kiehl, Senior Director at Eli Lilly and co-chair of the DTC's new pharma and regulatory Working Group. Doug discusses his 30-year tenure at Eli Lilly, the formation of the Disruptive/Transformative Technologies team, and the drivers for digital twin technology in pharma, including industry trajectory and regulatory expectations. He highlights the importance of cross-industry collaboration and the potential of digital twins in manufacturing, compliance, and process validation, emphasizing their role in expediting product development and improving patient outcomes. Action Items [ ] Attract other pharmaceutical companies to join the Digital Twin Consortium and contribute to working group efforts. [ ] Develop a charter and focus areas for the Pharma and Regulatory Working Group. [ ] Explore applications of digital twins across the pharmaceutical product development and manufacturing lifecycle. Outline Introduction and Welcome Karen Quatromoni introduces herself as the Director of Public Relations for Object Management Group (OMG) and welcomes Bill Hoffman and Doug Kiehl to the OMG podcast series. Karen highlights OMG's role in driving industry standards and building tech communities, and introduces the focus on the Digital Twin Consortium (DTC). Bill Hoffman introduces Doug Kiehl, Senior Director at Eli Lilly and Company's Disruptive/Transformative Team and Digital Twin Center of Excellence, and chair of the DTC's new pharma and regulatory Working Group. Doug Kiehl thanks Karen and Bill for the introduction and expresses his gratitude for organizing the podcast. Doug Kiehl's Background and Role at Eli Lilly Doug Kiehl shares his 30-year tenure at Eli Lilly, his experience in product development, and his roles in various capacities with government and private industry. He mentions his background as a mass spectrometrist and analytical chemist, and his role in forming the Disruptive/Transformative Technologies team at Eli Lilly. Doug explains the two main drivers for forming the Disruptive/Transformative Technologies team: industry trajectory and regulatory expectations. He highlights his involvement with the Product Quality Research Institute (PQRI) and his role as the chair for the PQRI steering committee, which includes FDA and Health Canada stakeholders. Formation of the Disruptive/Transformative Technologies Team Doug discusses the formation of the Disruptive/Transformative Technologies team one year ago, driven by the need for digital transformation in the pharmaceutical industry. He emphasizes the importance of cross-collaborative partnerships, mentioning his liaison with various industries, including defense, Air Force Research Labs, Army Research Labs, and NASA. Doug expresses his satisfaction with the Digital Twin Consortium for enabling access to these partnerships and advancing their goals. Bill Hoffman acknowledges Doug's impressive background and the strong connection between different industries applying digital twin technology. Charter and Importance of Digital Twins in Pharma Doug outlines the charter of the new working group, focusing on attracting other pharmaceutical companies to join the Digital Twin Consortium. He highlights the broad application of digital twin technology throughout the pharmaceutical product development and manufacturing life cycle, including supply chain and post-launch life cycle management. Doug mentions the importance of modeling clinical trials to minimize...